|
GB1351025A
(en)
*
|
1971-08-20 |
1974-04-24 |
Aron Md Samuel J |
Oxadiazol-5-yl biguanide derivatives method for their preparation and pharmaceutical compositions containing them
|
|
ZA876930B
(en)
|
1986-10-07 |
1988-05-25 |
Hoffmann La Roche |
Pharmaceutical compositions
|
|
IT1245890B
(it)
|
1991-04-12 |
1994-10-25 |
Alfa Wassermann Spa |
Formulazioni farmaceutiche per uso orale gastroresistenti contenenti acidi biliari.
|
|
GB9203347D0
(en)
|
1992-02-17 |
1992-04-01 |
Wellcome Found |
Hypolipidaemic compounds
|
|
US5415872A
(en)
|
1992-06-22 |
1995-05-16 |
Digestive Care Inc. |
Compositions of gastric acid-resistant microspheres containing salts of bile acids
|
|
US5234697A
(en)
|
1992-06-22 |
1993-08-10 |
Digestive Care Inc. |
Compositions of gastric acid-resistant microspheres containing salts of bile acids
|
|
IL108634A0
(en)
|
1993-02-15 |
1994-05-30 |
Wellcome Found |
Hypolipidaemic heterocyclic compounds, their prepatation and pharmaceutical compositions containing them
|
|
ZA941003B
(en)
|
1993-02-15 |
1995-08-14 |
Wellcome Found |
Hypolipidaemic compounds
|
|
KR970005178B1
(ko)
|
1993-12-28 |
1997-04-14 |
이승철 |
피로회복제 조성물
|
|
US5589358A
(en)
|
1993-12-29 |
1996-12-31 |
Univ Wake Forest |
Ileal bile acid transporter compositions and methods
|
|
ZA956647B
(en)
|
1994-08-10 |
1997-02-10 |
Wellcome Found |
Hypolipidaemic compounds.
|
|
US6642268B2
(en)
|
1994-09-13 |
2003-11-04 |
G.D. Searle & Co. |
Combination therapy employing ileal bile acid transport inhibiting benzothipines and HMG Co-A reductase inhibitors
|
|
US6262277B1
(en)
|
1994-09-13 |
2001-07-17 |
G.D. Searle And Company |
Intermediates and processes for the preparation of benzothiepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake
|
|
US6107494A
(en)
|
1994-09-13 |
2000-08-22 |
G.D. Searle And Company |
Substituted 5-aryl-benzothiepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake
|
|
US6268392B1
(en)
|
1994-09-13 |
2001-07-31 |
G. D. Searle & Co. |
Combination therapy employing ileal bile acid transport inhibiting benzothiepines and HMG Co-A reductase inhibitors
|
|
US5994391A
(en)
*
|
1994-09-13 |
1999-11-30 |
G.D. Searle And Company |
Benzothiepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake
|
|
GB9423172D0
(en)
|
1994-11-17 |
1995-01-04 |
Wellcom Foundation The Limited |
Hypolipidemic benzothiazepines
|
|
US6861053B1
(en)
|
1999-08-11 |
2005-03-01 |
Cedars-Sinai Medical Center |
Methods of diagnosing or treating irritable bowel syndrome and other disorders caused by small intestinal bacterial overgrowth
|
|
HUP9903047A3
(en)
|
1996-03-11 |
2002-12-28 |
G D Searle & Co Chicago |
Novel benzothiazepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake
|
|
DE122010000020I1
(de)
|
1996-04-25 |
2010-07-08 |
Prosidion Ltd |
Verfahren zur Senkung des Blutglukosespiegels in Säugern
|
|
US5908830A
(en)
|
1996-10-31 |
1999-06-01 |
Merck & Co., Inc. |
Combination therapy for the treatment of diabetes and obesity
|
|
GB9704208D0
(en)
*
|
1997-02-28 |
1997-04-16 |
Glaxo Group Ltd |
Chemical compounds
|
|
DK0864582T3
(da)
|
1997-03-14 |
2003-09-29 |
Aventis Pharma Gmbh |
Hypolidemiske 1,4-benzothiazepin-1,1-dioxider
|
|
US5900233A
(en)
|
1997-10-16 |
1999-05-04 |
Day; Charles E. |
Epichlorohydrin and 1-(3-aminopropyl) imidazole copolymer and its use in treating irritable bowel syndrome
|
|
ATE234829T1
(de)
|
1997-12-19 |
2003-04-15 |
Searle & Co |
Verfahren zu herstellung von enantiomerisch- anreicherte tetrahydrobenzothiepin oxyden
|
|
GB9800428D0
(en)
|
1998-01-10 |
1998-03-04 |
Glaxo Group Ltd |
Chemical compounds
|
|
EP2583675A1
(en)
|
1998-02-02 |
2013-04-24 |
Trustees Of Tufts College |
Use of dipeptidylpeptidase inhibitors to regulate glucose metabolism
|
|
JP2000026300A
(ja)
|
1998-07-02 |
2000-01-25 |
Pola Chem Ind Inc |
血管内皮細胞保護医薬組成物
|
|
JP2002533412A
(ja)
|
1998-12-23 |
2002-10-08 |
ジー．ディー．サール エルエルシー |
心臓血管に適用するための回腸胆汁酸輸送阻害剤およびコレステリルエステル転送タンパク質阻害剤の組み合わせ
|
|
SE9901387D0
(sv)
|
1999-04-19 |
1999-04-19 |
Astra Ab |
New pharmaceutical foromaulations
|
|
US6309663B1
(en)
|
1999-08-17 |
2001-10-30 |
Lipocine Inc. |
Triglyceride-free compositions and methods for enhanced absorption of hydrophilic therapeutic agents
|
|
CZ290178B6
(cs)
|
1999-07-22 |
2002-06-12 |
Sankyo Company Limited |
Deriváty cyklobutenu
|
|
EP1743655B1
(en)
|
2000-01-21 |
2014-06-25 |
Novartis AG |
Combinations comprising dipeptidylpeptidase-iv inhibitors and antidiabetic agents
|
|
SE0000772D0
(sv)
|
2000-03-08 |
2000-03-08 |
Astrazeneca Ab |
Chemical compounds
|
|
CA2401290A1
(en)
|
2000-04-12 |
2001-10-18 |
Takeda Chemical Industries, Ltd. |
Novel g protein-coupled receptor protein and dna thereof
|
|
US20020183307A1
(en)
*
|
2000-07-26 |
2002-12-05 |
Tremont Samuel J. |
Novel 1,4-benzothiazephine and 1,5-benzothiazepine compounds as inhibitors of apical sodium co-dependent bile acid transport and taurocholate uptake
|
|
RU2241462C2
(ru)
|
2000-07-28 |
2004-12-10 |
Ф. Хоффманн-Ля Рош Аг |
Новая фармацевтическая композиция
|
|
CN1466465A
(zh)
*
|
2000-08-01 |
2004-01-07 |
��Ұ����ҩ��ʽ���� |
肥胖或脂肪肝的预防或治疗药物
|
|
US7198914B2
(en)
|
2000-11-17 |
2007-04-03 |
Banyu Pharmaceutical Co., Ltd. |
Guanosine triphosphate (GTP)-binding protein-coupled receptor protein, BG37
|
|
EG26979A
(en)
|
2000-12-21 |
2015-03-01 |
Astrazeneca Ab |
Chemical compounds
|
|
WO2002053548A1
(fr)
*
|
2000-12-27 |
2002-07-11 |
Banyu Pharmaceutical Co.,Ltd. |
Derives de la benzothiazepine
|
|
AU2002306868A1
(en)
|
2001-03-28 |
2002-10-15 |
Pharmacia Corporation |
Therapeutic combinations for cardiovascular and inflammatory indications
|
|
US20030149010A1
(en)
|
2001-07-19 |
2003-08-07 |
Keller Bradley T. |
Combination of an aldosterone receptor antagonist and an HMG CoA reductase inhibitor
|
|
RS11104A
(sr)
|
2001-08-22 |
2006-12-15 |
Sanofi Aventis Deutschland Gmbh. |
Kombinovani preparati derivata 1,4-benzotiepin-1,1-dioksida sa drugim aktivnim supstancama i njihova primena
|
|
GB0121337D0
(en)
|
2001-09-04 |
2001-10-24 |
Astrazeneca Ab |
Chemical compounds
|
|
GB0121622D0
(en)
|
2001-09-07 |
2001-10-31 |
Astrazeneca Ab |
Chemical compounds
|
|
GB0121621D0
(en)
|
2001-09-07 |
2001-10-31 |
Astrazeneca Ab |
Chemical compounds
|
|
AU2002329387B2
(en)
|
2001-09-08 |
2007-06-07 |
Albireo Ab |
Benzothiazepine and benzothiadiazepine derivatives with ileal bile acid transport (IBAT) inhibitory activity for the treatment hyperlipidaemia
|
|
CA2776391C
(en)
|
2001-10-01 |
2015-03-31 |
The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Development of a preventive vaccine for filovirus infection in primates
|
|
BR0213501A
(pt)
|
2001-11-02 |
2004-08-24 |
Searle Llc |
Compostos de benzotiepina mono- e di-fluorada como inibidores de transporte de ácido biliar co-dependente de sódio apical (asbt) e captação de taurocolato
|
|
GB0229931D0
(en)
*
|
2002-12-21 |
2003-01-29 |
Astrazeneca Ab |
Therapeutic agents
|
|
US6852753B2
(en)
|
2002-01-17 |
2005-02-08 |
Pharmacia Corporation |
Alkyl/aryl hydroxy or keto thiepine compounds as inhibitors of apical sodium co-dependent bile acid transport (ASBT) and taurocholate uptake
|
|
GB0201850D0
(en)
|
2002-01-26 |
2002-03-13 |
Astrazeneca Ab |
Therapeutic treatment
|
|
US20040014806A1
(en)
|
2002-03-08 |
2004-01-22 |
Pharmacia Corporation |
Methods and compositions for lowering levels of blood lipids
|
|
GB0209467D0
(en)
|
2002-04-25 |
2002-06-05 |
Astrazeneca Ab |
Chemical compounds
|
|
MXPA04011584A
(es)
|
2002-05-23 |
2005-03-31 |
Umd Inc |
Composiciones y metodo para la administracion y crioproteccion de drogas transmucosales.
|
|
US7312208B2
(en)
*
|
2002-08-28 |
2007-12-25 |
Asahi Kasei Pharma Corporation |
Quaternary ammonium compounds
|
|
CN100494185C
(zh)
|
2002-08-28 |
2009-06-03 |
旭化成制药株式会社 |
新型季铵化合物
|
|
US20040122033A1
(en)
|
2002-12-10 |
2004-06-24 |
Nargund Ravi P. |
Combination therapy for the treatment of obesity
|
|
US20040138145A1
(en)
|
2002-12-12 |
2004-07-15 |
Aventis Pharma S.A. |
Application of intestinal biliary acid reuptake inhibitors for the prevention and treatment of alzheimer's disease
|
|
GB0304194D0
(en)
|
2003-02-25 |
2003-03-26 |
Astrazeneca Ab |
Chemical compounds
|
|
GB0307918D0
(en)
|
2003-04-05 |
2003-05-14 |
Astrazeneca Ab |
Therapeutic use
|
|
EP1635832A2
(en)
*
|
2003-06-06 |
2006-03-22 |
Merck & Co., Inc. |
Combination therapy for the treatment of diabetes
|
|
JP2005097216A
(ja)
|
2003-09-26 |
2005-04-14 |
Kaneka Corp |
ＰＰＡＲγリガンド剤
|
|
KR20070026392A
(ko)
|
2004-02-27 |
2007-03-08 |
아사히 가세이 파마 가부시키가이샤 |
신규 벤조티아제핀 및 벤조티에핀 화합물
|
|
EP1799263A4
(en)
|
2004-09-15 |
2009-07-29 |
Harvard College |
REDUCTION OF ER-STRESS IN THE TREATMENT OF ADIPOSITAS AND DIABETES
|
|
WO2006041150A1
(ja)
*
|
2004-10-15 |
2006-04-20 |
Mitsubishi Pharma Corporation |
糖尿病の予防および／または治療薬
|
|
AU2005299808B2
(en)
*
|
2004-10-25 |
2009-08-20 |
Novartis Ag |
Combination of DPP-IV inhibitor, PPAR antidiabetic and metformin
|
|
EP1819318A1
(en)
|
2004-11-24 |
2007-08-22 |
Seo Hong Yoo |
Dried forms of aqueous solubilized bile acid dosage formulation
|
|
WO2006086727A2
(en)
*
|
2005-02-09 |
2006-08-17 |
Entelos, Inc. |
Treating diabetes with glucagon-like peptide-1 secretagogues
|
|
US20060193895A1
(en)
|
2005-02-25 |
2006-08-31 |
Use-Techno Corporation |
Additive for food and beverage, pharmaceutical composition, GLUT4 translocator, and method for translocating GLUT4
|
|
FR2883284A1
(fr)
|
2005-03-15 |
2006-09-22 |
Commissariat Energie Atomique |
Nouveaux derives dihydropyrimidines et leur utilisation comme agents anti-cancereux
|
|
US20060222709A1
(en)
*
|
2005-03-18 |
2006-10-05 |
Agi Therapeutics Research Ltd. |
Metformin methods and formulations for treating chronic constipation
|
|
UY29445A1
(es)
|
2005-03-30 |
2006-10-02 |
Generex Pharm Inc |
Composiciones para la transmisión transmucosa oral de la metformina
|
|
US20080031968A1
(en)
|
2005-04-01 |
2008-02-07 |
The Brigham And Women's Hospital, Inc. |
Methods for increasing cellular energy expenditure
|
|
WO2006105912A2
(en)
|
2005-04-04 |
2006-10-12 |
Julius-Maximilians-Universität Würzburg |
Peptides that down regulate the activity of plasma membrane transporters including sodium-d-glucose cotransporter sglt1
|
|
AU2006231071B2
(en)
|
2005-04-04 |
2012-09-06 |
Julius-Maximilians-Universitaet Wuerzburg |
Tripeptides that down regulate the activity of plasma membrane transporters including sodium-D-glucose cotransporter SGLT1
|
|
WO2006116814A1
(en)
|
2005-05-02 |
2006-11-09 |
Vanadis Bioscience Ltd |
Composition and uses thereof
|
|
US20070025953A1
(en)
|
2005-07-27 |
2007-02-01 |
Jones Michael R |
Co-therapy for diabetic conditions
|
|
CA2623826A1
(en)
|
2005-09-30 |
2007-04-12 |
Novartis Ag |
Dpp iv inhibitor for use in the treatment of autoimmune diseases and graft rejection
|
|
JP5081161B2
(ja)
|
2005-12-19 |
2012-11-21 |
スミスクライン ビーチャム コーポレーション |
ファルネソイドｘ受容体アゴニスト
|
|
CN101404987A
(zh)
|
2006-01-20 |
2009-04-08 |
史密丝克莱恩比彻姆公司 |
磺酰胺衍生物在治疗代射和神经系统疾病中的用途
|
|
JP2010517931A
(ja)
|
2006-02-14 |
2010-05-27 |
インターセプト ファーマシューティカルズ， インコーポレイテッド |
Ｆｘｒ媒介性の疾患または状態の予防または治療用のｆｘｒリガンドとしての胆汁酸誘導体
|
|
PT2040713E
(pt)
|
2006-06-27 |
2014-10-13 |
Intercept Pharmaceuticals Inc |
Para a prevenção ou o tratamento de doenças ou estados clínicos mediados por fxr
|
|
US20080065136A1
(en)
|
2006-08-30 |
2008-03-13 |
Andrew Young |
Distender device and method for treatment of obesity and metabolic and other diseases
|
|
CL2007003035A1
(es)
|
2006-10-24 |
2008-05-16 |
Smithkline Beechman Corp |
Compuestos derivados de isoxazol sustituidos, agonistas de receptores farnesoid x; procedimiento de preparacion; composicion farmaceutica que lo comprende; y uso del compuesto en el tratamiento de la obesidad, diabetes mellitus, fibrosis en organos,
|
|
DE102006053635B4
(de)
|
2006-11-14 |
2011-06-30 |
Sanofi-Aventis Deutschland GmbH, 65929 |
Neue mit Benzylresten substituierte 1,4-Benzothiepin-1,1-Dioxidderivate, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
|
|
DE502007006208D1
(de)
|
2006-11-14 |
2011-02-17 |
Sanofi Aventis Deutschland |
Neue 1,4-benzothiepin-1,1-dioxidderivate mit verbesserten eigenschaften, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
|
|
WO2008067219A2
(en)
|
2006-11-29 |
2008-06-05 |
Kalypsys, Inc. |
Quinazolinone modulators of tgr5
|
|
AU2008209566C1
(en)
|
2007-01-19 |
2013-02-14 |
Intercept Pharmaceuticals, Inc. |
23-substituted bile acids as TGR5 modulators and methods of use thereof
|
|
US20080221161A1
(en)
|
2007-02-09 |
2008-09-11 |
Kalypsys, Inc. |
Heterocyclic modulators of tgr5 for treatment of disease
|
|
NZ583369A
(en)
|
2007-08-23 |
2011-08-26 |
Theracos Inc |
Benzylbenzene derivatives and methods of use
|
|
ES2663948T3
(es)
|
2008-11-19 |
2018-04-17 |
Intercept Pharmaceuticals, Inc. |
Moduladores de TGR5 y método de uso de los mismos
|
|
WO2010062861A2
(en)
|
2008-11-26 |
2010-06-03 |
Satiogen Pharmaceuticals, Inc. |
Bile acid recycling inhibitors for treatment of obesity and diabetes
|
|
CA2744697C
(en)
|
2008-11-26 |
2016-06-21 |
Satiogen Pharmaceuticals, Inc. |
Use of compositions comprising bile acids, salts, and mimics thereof for the treatment of obesity or diabetes
|
|
US20110065676A1
(en)
|
2009-06-24 |
2011-03-17 |
Schering Corporation |
Combination therapies comprising par1 antagonists with nar agonists
|
|
ES2552657T3
(es)
|
2010-05-26 |
2015-12-01 |
Satiogen Pharmaceuticals, Inc. |
Inhibidores del reciclado de ácidos biliares y saciógenos para el tratamiento de diabetes, obesidad, y afecciones gastrointestinales inflamatorias
|
|
ES2687027T3
(es)
|
2010-11-04 |
2018-10-23 |
Albireo Ab |
Inhibidores de ibat para el tratamiento de enfermedades hepáticas
|
|
DK2637646T3
(en)
|
2010-11-08 |
2016-08-29 |
Albireo Ab |
PHARMACEUTICAL COMBINATION CONTAINING AN IBAT inhibitor and a bile acid binder
|
|
WO2012064268A1
(en)
|
2010-11-08 |
2012-05-18 |
Albireo Ab |
Ibat inhibitors for treatment of metabolic disorders and related conditions
|